The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats

Investigative Radiology

Volumn 46, Issue 1, 2011, Pages 48-56

  Pietsch, Hubertus ^a   Raschke, Marian ^a   Ellinger Ziegelbauer, Heidrun ^a   Jost, Gregor ^a   Walter, Jakob ^a   Frenzel, Thomas ^a   Lenhard, Diana ^a   Hütter, Joachim ^a   Sieber, Martin A ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

complex stability; gadolinium; gadolinium based contrast agents; nephrogenic systemic fibrosis

Indexed keywords

BETA 2 MICROGLOBULIN; CLUSTERIN; CYSTATIN C; CYTOKINE; FIBROBLAST GROWTH FACTOR 9; GADODIAMIDE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; LYMPHOTACTIN; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; ONCOSTATIN M; OSTEOPONTIN; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TISSUE LEVEL; IDIOPATHIC DISEASE; KIDNEY FAILURE; M MODE ECHOCARDIOGRAPHY; MASS SPECTROMETRY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN BIOPSY; SKIN FIBROSIS; TECHNOLOGY;

EID: 78650700629     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181efd49a     Document Type: Article

References (47)

1. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol. 2006;18:614-617.
2. Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am. 2009;47:833-840, vi.
3. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383-393.
4. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660-2666.
5. Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol. 2008;5:36-39.
6. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238-249.
7. Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol. 2008;58:1025-1030.
8. Gambichler T, Kreuter A, Skrygan M, et al. Decorin is significantly overex-pressed in nephrogenic systemic fibrosis. Am J Clin Pathol. 2009;132:139-143.
9. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214:199-210.
10. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009;5:200-206.
11. Grobner T. Gadolinium-a specific trigger for the development of nephro-genic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:3604-3605.
12. Marckmann P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Radiol. 2008;66:187-190.
13. FDA. Meeting Materials, Cardiovascular and Renal Drugs Advisory Committee. Volume 2010; 2009. Available at: http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenal DrugsAdvisoryCommittee/ucm125999.htm.
14. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology. 2008;248:799-806.
15. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816.
16. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
17. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglu-mine. Invest Radiol. 2009;44:135-139.
18. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol. 2007;42:139-145.
19. Sieber MA, Steger-Hartmann T, Lengsfeld P, et al. Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging. 2009;30:1268-1276.
20. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164-2173.
21. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging. 2008;27:955-962.
22. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
23. Haylor JL, Dencausse H, Vickers M, et al. Increased skin cellularity following Omniscan in rats with reduced renal function. Euro Radiol. 2009;19(suppl 1):S284.
24. Hope TA, High WA, Leboit PE, et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology. 2009;253:390-398.
25. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis-a mechanistic hypothesis based on preclinical results from a rat model treated with gadodia-mide. Exp Toxicol Pathol. 2009;61:537-552.
26. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44: 226-233.
27. Pietsch H, Jost G, Frenzel T, et al. Efficacy and safety of lanthanoids as X-ray contrast agents. Eur J Radiol. 2009 Dec. 16. [Epub ahead of print.]
28. Perone PA, Weber SL, DaSilva M, et al. Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol. 2010;45:42-48.
29. Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol. 2009;44:433-439.
30. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol. 2008;214:584-593.
31. Abraham JL, Edward M. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis. Am J Roentgenol. 2009;193:W354; author reply W355.
32. Varani J, Dasilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74-81.
33. Fu LJ, Li JX, Yang XG, et al. Gadolinium-promoted cell cycle progression with enhanced S-phase entry via activation of both ERK and PI3K signaling pathways in NIH 3T3 cells. J Biol Inorg Chem. 2009;14:219-227.
34. Vakil V, Sung JJ, Piecychna M, et al. Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. J Magn Reson Imaging. 2009;30:1284-1288.
35. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27-30.
36. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
37. Crissman JW, Goodman DG, Hildebrandt PK, et al. Best practices guideline: toxicologic histopathology. Toxicol Pathol. 2004;32:126-131.
38. Greaves P. ed. Integumentary System. Amsterdam, London: Elsevier; 2000: 1-54.
39. Klein-Szanto A, Conti C. Skin and oral mucosa. In: Haschek W, Rousseaux C, Wallig M, eds. Handbook of Toxicology Pathology. San Diego, San Francisco, CA: Academic Press; 2002:85-119.
40. Pietsch H, Pering C, Lengsfeld P, et al. Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. J Magn Reson Imaging. 2009;30:374-383.
41. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol. 2008;158:273-280.
42. Pietsch H, Lengsfeld P, Jost G, et al. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol. 2009;19:1417-1424.
43. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:710-712.
44. Hasegawa M, Sato S. The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front Biosci. 2008;13:3637-3647.
45. Distler JH, Akhmetshina A, Schett G, et al. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford). 2009;48:98-103.
46. Junker U, Haufe CC, Nuske K, et al. Elevated plasma TGF-beta1 in renal diseases: cause or consequence? Cytokine. 2000;12:1084-1091.
47. Leung N, Shaikh A, Cosio FG, et al. The outcome of patients with nephro-genic systemic fibrosis after successful kidney transplantation. Am J Transplant. 2010;10:558-562.